RespireRx Pharmaceuticals Inc (RSPI)

[neuroinv]

Some answers:
1) They brought it forward for an adult ADHD population first, for a disorder where there is a lot of demand for a nonstimulant option, demand which has allowed a very poor drug, Strattera, to garner $500 million plus in sales per year.
2) The collaboration with Greer was, I believe, signed in summer 07. The ADHD project was 'all in' at that time. If you have a deal--as I have heard--that would have paid $30 million plus upfront, and you don't think that the flaw is inherent to the molecule-- I hear people now saying, with 20:20 hindsight, that they would have dumped the molecule and started again--putting Cortex at least a year behind schedule. I honestly doubt that anyone contributing seriously to this board would actually have made that choice, at the time, based on what was known then. I know I wouldn't have. The same people who say that Cortex should have 'fought' the FDA think that they should have given up on CX717, which is a bizarre combination of confrontation and surrender. The latter had a lot more chance of success than the former.
3) I think Cortex management will take the best deal available, I don't think they would dismiss anything out-of-hand at this point. An indication-based deal, a low impact platform deal, a buyout, I believe they are all on the table.

NeuroInvestment